Analyst Price Targets — ABEO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 17, 2026 7:53 pm | Stephen Willey | Stifel Nicolaus | $17.00 | $4.76 | StreetInsider | Abeona Therapeutics (ABEO) PT Lowered to $17 at Stifel on Zevaskyn sales estimates |
| May 16, 2025 12:02 pm | Stephen Willey | Stifel Nicolaus | $20.00 | $6.10 | TheFly | Abeona Therapeutics price target lowered to $20 from $21 at Stifel |
| March 5, 2025 12:18 pm | — | Oppenheimer | $16.00 | $5.26 | TheFly | Abeona Therapeutics initiated with an Outperform at Oppenheimer |
| November 14, 2022 1:42 pm | — | Leerink Partners | $6.00 | $4.15 | Benzinga | SVB Leerink Maintains Market Perform on Abeona Therapeutics, Raises Price Target to $6 |
Latest News for ABEO
CLEVELAND, May 04, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it will host a conference call on Wednesday, May 13, 2026 at 8:30 a.m. ET to discuss its financial results for the first quarter of 2026 and corporate progress.
CLEVELAND, May 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
CLEVELAND, April 07, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Keith A. Goldan as a new independent member to its Board of Directors, effective as of April 1, 2026. Mr. Goldan will also serve as Chairman of Abeona's Audit Committee. Mr. Goldan brings more than two decades of financial leadership experience across publicly traded commercial-stage biotechnology…
CLEVELAND, April 06, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
CLEVELAND, April 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of NewYork-Presbyterian/Columbia University Irving Medical Center in New York, NY as the newest Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. “Activation of NewYork-Presbyterian/Columbia University Irving Medical Center as our…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ABEO.
U.S. House Trading
No House trades found for ABEO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.